1 / 46

Renal Tumors

Renal Tumors. Part II Scott Wilkinson, DO, MS. Treatme nt Pearls. Obstacles Towards Treatment . RCC is historically resistant to many types of treatment Chemotherapy (MDR-1) Radiation Very aggressive in nature (TGF alpha and EGFR) Highly vascular (VEGF secondary to loss of vHL)

evaline
Télécharger la présentation

Renal Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Renal Tumors Part II Scott Wilkinson, DO, MS

  2. Treatment Pearls

  3. Obstacles Towards Treatment • RCC is historically resistant to many types of treatment • Chemotherapy (MDR-1) • Radiation • Very aggressive in nature (TGF alpha and EGFR) • Highly vascular (VEGF secondary to loss of vHL) • Expresses tumor-associated antigens (PRAME, RAGE-1, gp75, and MN-9) which contributes to its immunogenicity

  4. Tx of Localized RCC • Radical nephrectomy • Nephron-sparing surgery (NSS) • NSS with normal opposite kidney • NSS with vHL disease • Thermal ablative therapies • Observation

  5. Radical nephrectomy • Robson and colleagues “gold standard” 1969 • Prototype – A then B, Gerota’s intact, ipsi adrenal, LND (crus to aortic bifurcation) • Now – no adrenal if: no rad evidence unless extensive renal involvement, locally advanced, located upper pole, immediately adjacent to adrenal

  6. Today – LND = controversial • Heme & Lymph spread • Lymphatic drainage variable • <2-3% benefit • However, more accurate staging • Risk factors indicating LND • High tumor grade • Sarcomatoid component • Histologic tumor necrosis • Large size (> 10 cm) • pT3 or pT4 • *incidence 10% with 2 or >, 0.6% if <

  7. Surgical approach determined by size, location of tumor and body habitus • Transperitoneal • Subcostal • thoracoabdominal • Extraperitoneal • Flank • Laparoscopic (trans, retro, hand-assist)

  8. Laparoscopic • Cancer specific survival comparable to open • Usually < 8-10cm; localized with no local invasion, renal vein involvement, or lymphadenopathy

  9. RN Surveillance Stage H/E/labs CXR CTa/p • T1NOMO yearly ---- ---- • T2NOMO yearly yearly q 2 yrs • T3a-cNOMO q 6m x 3 yr - yr same 1yr then q 2 yr • Bone scans, plain xr, and head CT if clinically indicated

  10. Nephron-Sparing Surgery • Czerny 1890 • Vermooten 1950 – NSS • Indications include situations where pt would be anephric or high risk of needing HD • Solitary kidney RCC • Bilateral RCC • Contralateraldz (RAS, Hydro, chronic pyelo, reflux, stones, DM, nephrosclerosis)

  11. A functional remnant of at least 20% of one normal kidney is necessary to avoid end-stage renal failure • IF solitary kidney, > 50% reduction in renal mass = incr risk of hyperfiltration renal injury (proteinuria, focal segmental glomerulosclerosis, progressive renal failure) • Prevention: Protein restriction & ACEI

  12. Preoperative testing • r/o local extension, mets, vascular/collecting system relationship • Renal angio, veno, 3DCT or MRI • Cancer-specific survival rates 78-100% • Recurrence – undetected dz in remnant • Complications – majority hemorrhagic

  13. NSS Surveillance Stage H/E/labs CXR CTa/p • T1NOMO yearly ---- ---- • T2NOMO yearly yearly q 2 yrs • T3NOMO q 6m x 3 yr - yr same q6m x3y –q2yr

  14. NSS with normal opposite kidney • CSS 5yr 100% with small unilat T1-2 • Licht et al 1994 (< 4 cm) • CSS 5 yr central vs peripheral (100 vs 97%), tumor recurrance (5.7 vs 4.5%), renal fxn equivocal • Hafez et al 1999 • Adv: 17-28% excised = benign (MSK)

  15. NSS in vHL disease • Differs via – young age @ dx, usually multiple bilateral tumors • Solid and cystic (lining of hyperplastic clear cells) • Intraop US may help to get all • Options – B/l RN, PN & RN, B/l PN • High incidence of recurrence in remnant 27.4% • Duffey and colleuges 2004 – 3 cm threshold

  16. Thermal ablative • Both perc or lap approach • Lack of histo/path staging • ? High recurrence rate • Ideal – advanced age, comorbidities, local recurrance, hereditary renal cancer • Cryosurgery • Repetition of freeze-thaw cycle (-20C) • Immediate cellular cryodestruction and delayed microcirculatory failure. • Radiofrequency ablation • 45C irreversible cell damage • 55-60C immediate cell death

  17. Thermal Ablative Pearls • In general, enhancement within the tumor bed on extended follow-up has been considered diagnostic of local recurrence, and the clinical experience thus far has supported this

  18. Observation • Median growth rate 0.36 cm/yr • Alternative for asymptomatic elderly and poor surgical risk, consider with solid/small/enhancing/well-marginated/homogeneous • Serial imaging 6mo or 1yr intervals • Not appropriate: >3cm, poor margins, nonhomogeneous, young healthy with abn imaging

  19. Tx of Locally Advanced RCC • IVC involvement • Locally invasive RCC • Local recurrence after RN or NSS • Adjuvant therapy for RCC

  20. IVC Involvement • Unique feature of RCC • 45-70% of RCC with IVC thrombus cured • Local extension/invasion much higher risk of recurrence • Occurs 4-10% of patients • Suspect with : LE edema, R varicocele, distended abd veins, proteinuria, PE, R atrial mass, nonfxn kidney

  21. IVC Thrombus staging • I – adjacent to ostium of renal vein • II – extends up to liver • III – intrahepatic portion of IVC below diaphragm • IV – above the diaphragm • Imaging • ? CT & AUS • Occasional TEE and TA doppler • Contrast inferior venacavography – if prob with MRI • MRI – study of choice • ? Renal arteriography

  22. Locally Invasive RCC • Present with pain from invasion of posterior abd wall, nerve roots or paraspinous muscles • Duodenal & pancreas uncommon • En bloc may be beneficial • Partial / debulking – only 12% alive in 1 yr • Preoperative rad – not beneficial (van derWerf-Messing 1973) • Residual tumor, rad may retard growth (Kao et al 1994)

  23. Local Recurrence after RN or NSS • LR in RN – 2-4% • Risk factors – T stage, local adv, node + disease • LR in NSS – 1.4-10% • Risk factors – T stage • Most LR occur distant to tumor bed • *pts with isolated recurrence after PN can ? Repeat PN

  24. Adjuvant Therapy for RCC • Include hormonal manipulation, radiotherapy, vaccines, cytokines, etc… • Most studies to date – not significant • Vaccine – irradiated tumor cells/BCG, heat shock proteins (HSPPC) = no proven benefit • Interferon alfa – modest survival benefit • IL-2 – no benefit

  25. Tx of Metastatic RCC • Nephrectomy • Hormonal therapy • Chemotherapy • Radiation therapy • Cytokines and Immunologic therapy • Multimodal therapy

  26. Nephrectomy • 1/3rd of RCC have mets • 40-50% will develop mets after initial dx • Regression of mets after RN – 1-2% (lung) • Benefit for synchronous mets with interferon alfa after RN • Individuals with: adv dz (PS > 2), mets (CNS, SC compression), MOD, significant comorbidities – not candidate

  27. Hormone Therapy • Minimal value • Progesterone – inhibit growth of DES-induced renal tumors in Syrian hamsters • No correlation with human RCC • Progestational agents = useful for symptom palliation

  28. Chemotherapy • 1980s – chemo-resistant tumor • Variety of agents RR 6% • Yagoda and assoc 1995 • In past, fluoropyrimidines & vinblastine – RR 2.5% (better with Vin and I-alfa) • Uniformly discouraging • MDR-1 (P-glycoprotein) = efflux pump reducing intracellular [] of agents • ? Role of Ca channel blockers, cyclosporine • Metastatic Non-clear cell or sarcomatoid diff – (doxorubicin & gemcitabine) RR 39% • Anecdotal responses with collecting duct cancers with cisplatin & gemcitabine

  29. Radiation Therapy • Considered as the primary therapy for palliation • Dose of 4500 centigray (cGy) is delivered, with consideration of a boost up to 5500 cGy • Preoperative radiation therapy yields no survival advantage • Palliative radiation therapy often is used for local or symptomatic metastatic disease

  30. Cytokines and Immunologic Therapy • Interferon alfa – protein with antiviral, immunomodulatory and antiproliferative activity • IL-2 – stimulates cell mediated immunity (cytotoxic T cells) • Single agent ORR – 13-15% • Combination > 20%, no change OS • Most effective regimen for IL-2 = high dose • SE – vascular leak (HypoTN, oliguria, organ failure = tx IVF) • *Improved OS with combo (vin, 5-FU, IL-2)

  31. Treatment Multi-kinase inhibitors (VEGF and PDGF) • Sorafenib (Nexavar) – OS 3 months • Dec 2005 FDA - 769 patients randomized • median PFS was 6 mo sorafenib vs. 3 mo placebo • 7 (2%) sorafenib patients and 0 (0%) placebo patients had confirmed partial responses. • Sunitinib (Sutent) • FDA in January 2006 • (40% partial responses) and a median time to progression of 8.7 months and an overall survival of 16.4 months • Bevacizumab (IgG1 monoclonal ab • Time to progression 4.8 mo vs placebo 2.5 mo • Combo with erlotinib – ORR 26% with PFS 11 mo

  32. Multimodal Therapy • Synchronous mets = RN then systemic therapy (IL-2, I-a, kinase inhibitors) • Most = RN first • Alternative – delayed RN and only patients showing regression or stability of mets get surgery • Solitary mets = metatectomy (pulm have more favorable prognosis, > 12mo)

  33. Other Malignant Renal Tumors • Sarcomas of the kidney • Renal lymphoma and leukemia • Metastatic tumors • Other malignant tumors of the kidney

  34. Sarcomas of the kidney • 1-2% of adult malignant tumors • 5th decade • Rapid growth +/- lymphadenopathy • Derived mesenchymal components (free of barriers) • Pseudocapsule • Tx RN with enbloc • Chemo (doxycycline and ifosfamide) have shown some activity • Combo rad / chemo – not well defined for renal

  35. Leiomyosarcoma – most common • 50-60% • Origin – smooth muscle • Female / 4th to 6th decade Liposarcoma – confused with AML • +/- response to rad/cisplatin • Osteogenic sarcoma –Calcium /rock hard *Less common – rhadomyosarcoma, fibrosarcoma, carcinosarcoma, angiosarcoma, malignant hemangiopericytoma (very vascular)

  36. Renal Lymphoma and Leukemia • Found in autopsy of 34% pts with L or L • Renal involvement more common with Non-Hodgins • B symptoms – fever, wt loss, fatigue • Hemedissem – 90% • Suspect with mass RPLA, splenomegaly, LA elsewhere • Renal leukemia more common in children (ALL > AML) • Percbx, chemo +/- rad (CHOP)

  37. Metastatic tumors • Most common malignant tumor of the kidney • Sources – lung, breast, GI, malignant melanoma • Suspect with – multiple renal lesions and widespread mets or a h/o nonrenal primary ca = Bx

  38. Other Malignant Tumors of the Kidney • Carcinoid (neuroedocrine cells) – rare • Correlation with horseshoe kidney • Check urine or plasma serotonin • Minority – carcinoid syndrome (episodic flushing, wheezing, diarrhea) • Surgical exision is mainstay of tx • NSS preferred • Colon/EGD r/o multifocal

  39. Wilm’s • 3% seen in adults • Triphasic • Staging and tx same as for children • Multimodal therapy (surg, chemo, +/- rad) • Prognosis worse in adults

  40. PNET (primitive neuroectodermal tumor) • Related to Ewing’s sarcoma • Derived from neural crest cells • Hist – small round cells (Homer Wright rosettes) • Difficult to differentiate from RCC • Multimodal tx (RN or debulk, chemo, rad)

  41. Small cell carcinoma • Locally advanced or metastatic at presentation • Multimodal tx (RN or debulk with platinum based chemo)

  42. Paraneoplastic Syndromes • Up to 30% of RCC patients • Reversible with tumor resection • If persist after resection, r/o mets • Syndromes • Elevated ESR • Wt loss, cachexia • Fever • Anemia • HTN (increased renin) • Hypercalcemia (PTH like substance • Stauffer’s syndrome • Elevated Alkphos • Polycythemia (incr erythropoietin)

  43. Management of Para-neoplastic Problems • Hypercalcemia • Pamidronate or zolendronate • These may also alter the bone microenvironment in a way that interrupts tumor growth • Inhibits osteoclastic activity • Hydration • Diuretics • Steroids • Calcitonin • Resolve with nephrectomy

  44. Palliative / supportive care • Pain, bleeding • Analgesic medications • XRT to sites of painful mets (esp bone mets) • XRT for cord compression • Arterial embolization • No survival benefit but can relieve Sx • “Clot colic” • Ureteral stents • hydration

  45. References • Wein, Alan J.; et al; Campbell-Walsh Urology, Saunders publishing, 9th edition, chapter 47, pages 1608-37. • Hanno, Philip M.; et al; Clinical Manual of Urology, McGraw-Hill Publishing, 3rd edition, pages 487-502. • Wieder, Jeff A.; Pocket Guide To Urology, Griffith Publishing, 3rd edition, pages 1-20.

  46. Questions

More Related